WEBULL
News
TENX
12.73
-2.12%
-0.28
Weekly Report: what happened at TENX last week (0202-0206)?
Weekly Report · 3d ago
Tenax Therapeutics nimmt an Guggenheim Emerging Outlook Biotech Summit teil
Reuters · 02/04 12:00
Weekly Report: what happened at TENX last week (0126-0130)?
Weekly Report · 02/02 10:05
Weekly Report: what happened at TENX last week (0119-0123)?
Weekly Report · 01/26 10:04
Weekly Report: what happened at TENX last week (0112-0116)?
Weekly Report · 01/19 10:09
Weekly Report: what happened at TENX last week (0105-0109)?
Weekly Report · 01/12 10:09
Tenax Therapeutics Updates Chief Medical Officer Agreement
TipRanks · 01/09 22:03
Tenax Therapeutics Prorates CMO Salary for Reduced Work Schedule
Reuters · 01/09 21:34
Tenax Therapeutics: A Speculative Buy
Seeking Alpha · 01/09 06:51
Tenax Therapeutics: How Lower Variance In Phase 3 Has "Loaded The Dice" For An Asymmetric Repricing
Seeking Alpha · 01/05 18:19
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 01/05 12:05
Weekly Report: what happened at TENX last week (1229-0102)?
Weekly Report · 01/05 10:04
Weekly Report: what happened at TENX last week (1222-1226)?
Weekly Report · 12/29/2025 10:03
Weekly Report: what happened at TENX last week (1215-1219)?
Weekly Report · 12/22/2025 10:03
Roth MKM Reaffirms Their Buy Rating on Tenax Therapeutics (TENX)
TipRanks · 12/18/2025 13:36
Optimistic Outlook on Tenax Therapeutics: Buy Rating Backed by Promising Clinical Developments
TipRanks · 12/17/2025 17:35
Tenax Therapeutics Advances Phase 3 Study on Levosimendan for PH-HFpEF
TipRanks · 12/17/2025 16:32
Tenax Therapeutics Advances LEVEL Phase 3 Study With Enrollment Completion Expected in 2026
Reuters · 12/17/2025 15:10
Tenax Therapeutics reports result of prespecified blinded sample size assessment
TipRanks · 12/17/2025 14:26
Tenax Therapeutics Announces Prespecified Blinded Sample Size Re-Estimation Of LEVEL Demonstrated Trial Is Powered At Well Over 90% To Detect 25 Meter Change In 6MWD, Primary Endpoint
Benzinga · 12/17/2025 14:20
More
Webull provides a variety of real-time TENX stock news. You can receive the latest news about Tenax Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About TENX
Tenax Therapeutics, Inc. is a Phase 3 development-stage pharmaceutical company. The Company is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The Company's products include TNX-201 (oral enteric-coated imatinib) and TNX-103 (oral levosimendan). The Company is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 and TNX-102. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Company has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).